Discontinued — last reported Q2 '17
Long-Term Debt - Fair Value
Merck & Co. Long-Term Debt - Fair Value increased by 21.0% to $45.60B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 39.9%, from $32.60B to $45.60B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt - Fair Value shows an upward trend with a 4.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase relative to book value may indicate rising interest rates or changes in credit risk, while a decrease may suggest favorable refinancing opportunities.
Detailed definition
This represents the estimated market value of the company's long-term debt obligations if they were to be settled or tra...
Peer comparison
Standard across large-cap pharmaceutical firms, often compared against total debt to assess interest rate sensitivity.
long_term_debt_fair_valueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $29.50B | $29.10B | $35.70B | $31.70B | $29.00B | $25.90B | $26.70B | $28.20B | $34.00B | $29.50B | $32.00B | $30.40B | $33.50B | $35.20B | $32.60B | $30.60B | $31.30B | $37.70B | $45.60B |
| QoQ Change | — | -1.4% | +22.7% | -11.2% | -8.5% | -10.7% | +3.1% | +5.6% | +20.6% | -13.2% | +8.5% | -5.0% | +10.2% | +5.1% | -7.4% | -6.1% | +2.3% | +20.4% | +21.0% |
| YoY Change | — | — | — | — | -1.7% | -11.0% | -25.2% | -11.0% | +17.2% | +13.9% | +19.9% | +7.8% | -1.5% | +19.3% | +1.9% | +0.7% | -6.6% | +7.1% | +39.9% |
Long-Term Debt - Fair Value at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s long-term debt - fair value?
- Merck & Co. (MRK) reported long-term debt - fair value of $45.60B in Q4 2025.
- How has Merck & Co.'s long-term debt - fair value changed year-over-year?
- Merck & Co.'s long-term debt - fair value increased by 39.9% year-over-year, from $32.60B to $45.60B.
- What is the long-term trend for Merck & Co.'s long-term debt - fair value?
- Over 5 years (2020 to 2025), Merck & Co.'s long-term debt - fair value has grown at a 4.8% compound annual growth rate (CAGR), from $36.00B to $45.60B.
- What does long-term debt - fair value mean?
- The current market value of the company's long-term debt obligations.